Teleflex Incorporated (NYSE:TFX) Director Benson Smith Sells 8,500 Shares

Teleflex Incorporated (NYSE:TFX) Director Benson Smith sold 8,500 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $305.83, for a total value of $2,599,555.00. Following the transaction, the director now directly owns 84,913 shares in the company, valued at approximately $25,968,942.79. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Benson Smith also recently made the following trade(s):

  • On Thursday, March 28th, Benson Smith sold 8,500 shares of Teleflex stock. The stock was sold at an average price of $300.15, for a total value of $2,551,275.00.

Shares of TFX stock opened at $300.36 on Friday. Teleflex Incorporated has a 1-year low of $226.02 and a 1-year high of $309.99. The company has a quick ratio of 1.39, a current ratio of 2.12 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $13.73 billion, a PE ratio of 30.34, a P/E/G ratio of 1.92 and a beta of 1.01.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, May 2nd. The medical technology company reported $2.24 EPS for the quarter, beating the consensus estimate of $2.17 by $0.07. Teleflex had a return on equity of 18.47% and a net margin of 8.20%. The company had revenue of $613.60 million for the quarter, compared to analyst estimates of $608.27 million. During the same quarter in the prior year, the company earned $2.15 EPS. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, research analysts predict that Teleflex Incorporated will post 11.03 earnings per share for the current year.

TFX has been the subject of several recent research reports. Needham & Company LLC restated a “strong-buy” rating and issued a $325.00 price target (up from $300.00) on shares of Teleflex in a research note on Friday, February 22nd. Barclays set a $287.00 price target on Teleflex and gave the company a “hold” rating in a research note on Friday, February 22nd. Zacks Investment Research upgraded Teleflex from a “sell” rating to a “hold” rating in a research report on Tuesday, February 26th. Morgan Stanley upped their target price on Teleflex from $305.00 to $315.00 and gave the company an “overweight” rating in a research report on Tuesday, February 26th. Finally, UBS Group boosted their price target on Teleflex to $350.00 and gave the stock a “buy” rating in a report on Friday, March 22nd. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $316.13.

Several institutional investors have recently made changes to their positions in TFX. Norges Bank purchased a new stake in shares of Teleflex during the fourth quarter valued at approximately $104,380,000. National Pension Service increased its position in shares of Teleflex by 5.5% during the fourth quarter. National Pension Service now owns 58,026 shares of the medical technology company’s stock valued at $16,335,000 after acquiring an additional 3,026 shares during the last quarter. LPL Financial LLC purchased a new stake in shares of Teleflex during the third quarter valued at approximately $234,000. First Citizens Bank & Trust Co. increased its position in shares of Teleflex by 8.3% during the fourth quarter. First Citizens Bank & Trust Co. now owns 1,734 shares of the medical technology company’s stock valued at $448,000 after acquiring an additional 133 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its position in shares of Teleflex by 1.8% during the fourth quarter. State of Alaska Department of Revenue now owns 4,986 shares of the medical technology company’s stock valued at $1,287,000 after acquiring an additional 87 shares during the last quarter. Institutional investors own 91.64% of the company’s stock.

WARNING: This piece of content was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/insider-selling-teleflex-incorporated-tfx-director-sells-8500-shares-of-stock.html.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Featured Article: Overbought

Insider Buying and Selling by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.